Pipeline - Allinky Biopharma

Go to content

Main menu:

Allinky is currently advancing the development of innovative proprietary molecules (allosteric inhibitors) through different drug development programs. These therapeutic molecules aim to be helpful in the treatment of neurodegenerative diseases such as AD (Alzheimer's Disease) and AMD (Age-related macular degeneration); respiratory diseases such as IPF (Idiopathic pulmonary fibrosis) and COPD (chronic obstructive pulmonary disease); and cancer, in particular tumor growth driven by the Ras family of proto-oncogenes that are found in lymphoma as well as in lung, colorectal and pancreatic cancer. All these molecules have been discovered by Allinky using its proprietary technology platform for the discovery of allosteric inhibitors.


Back to content | Back to main menu